Back to Journals » Drug Design, Development and Therapy » Volume 6

Exploring prospects of novel drugs for tuberculosis

Authors Janssen, Jayachandran, Khathi, Zinsstag, Grobusch M, Pieters

Received 18 May 2012

Accepted for publication 28 June 2012

Published 7 September 2012 Volume 2012:6 Pages 217—224

DOI https://doi.org/10.2147/DDDT.S34006

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2



Saskia Janssen,1,2 Rajesh Jayachandran,3 Lulama Khathi,4 Jakob Zinsstag,5 Martin P Grobusch,1,2,6 Jean Pieters3

1Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands; 2Institute of Tropical Medicine, University of Tübingen, Germany; 3Biozentrum, University of Basel, Basel, Switzerland; 4National Reference Laboratory for Tuberculosis, National Health Laboratory Services, Johannesburg, South Africa; 5Swiss Tropical and Public Health Institute, Associated Institute to the University of Basel, Basel, Switzerland; 6Department of Infectious Diseases, Division of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Abstract: Tuberculosis remains a disease with an enormous impact on public health worldwide. With the continuously increasing epidemic of drug-resistant tuberculosis, new drugs are desperately needed. However, even for the treatment of drug-sensitive tuberculosis, new drugs are required to shorten the treatment duration and thereby prevent development of drug resistance. Within the past ten years, major advances in tuberculosis drug research have been made, leading to a considerable number of antimycobacterial compounds which are now in the pipeline. Here we discuss a number of these novel promising tuberculosis drugs, as well as the discovery of two new potential drug targets for the development of novel effective drugs to curb the tuberculosis pandemic, ie, the coronin 1 and protein kinase G pathways. Protein kinase G is secreted by mycobacteria and is responsible for blocking lysosomal delivery within the macrophage. Coronin 1 is responsible for activating the phosphatase, calcineurin, and thereby preventing phagosome-lysosome fusion within the macrophage. Blocking these two pathways may lead to rapid killing of mycobacteria.

Keywords: tuberculosis, treatment, drug-resistance, drug targets

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.